The FDA on January 25, 2022, approved KIMMTRAK®, a bispecific gp100 peptide-HLA-directed CD3 T cell engager, for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. KIMMTRAK® is a product of Immunocore Limited.
Other Pages – Bottom Ad
Advertisement
Subscribe
